Modulation of [99mTc]Tc-iPSMA preparation conditions reduces radiochemical species heterogeneity and supports a single-vial cold-kit formulation
Introduction Technetium-99 m labeling of hydrazinonicotinamide (HYNIC)-conjugated vectors requires transfer ligands and co-ligands that may generate multiple radiochemical species with slightly different physicochemical and biological properties. This study aimed to optimize the radiolabeling of the HYNIC-conjugated prostate-specific membrane antigen ligand iPSMA to reduce chromatographic heterogeneity while maintaining high radiochemical purity (RCP), and to translate the selected conditions into a single-vial cold-kit formulation. Methods Twenty radiolabeling conditions were evaluated through 3 replicates each by independently varying the co-ligand, transfer ligand, buffer, reducing agent, antioxidant, reaction time, and reaction temperature. Products were characterized by radio-HPLC and radio-TLC. The optimized conditions were subsequently applied to freeze-dried single-vial formulations containing one of five bulking agents. The effects of bulking-agent content, technetium-99 m activity, heating time, and pertechnetate eluate age were also investigated. Results The reference protocol yielded an RCP of 90.31 ± 0.83%, with the predominant radiolabeled species accounting for 76.97 ± 2.53% of the radiocomplexes. Among the investigated parameters, reaction-medium composition, particularly the buffer used, had the greatest influence on the chromatographic distribution of radiolabeled species. Using sodium acetate 0.2 M at pH 7 with EDDA and tricine increased RCP to 95.15 ± 0.29% and the proportion of the predominant radiolabeled species to 96.21 ± 0.23%. Reduced/hydrolyzed technetium remained below the radio-TLC detection limit. Mannitol provided the best cold-kit performance and was selected at 40 mg per vial. Under the present formulation conditions, satisfactory kit performance was obtained with ≤1.5 GBq of freshly eluted pertechnetate (<30 min), with 0.92 ± 0.11% residual pertechnetate, 91.47 ± 2.66% major radiolabeled species, and a RCP of 95.69 ± 1.28%. Conclusion Radio-HPLC-guided optimization markedly reduced radiochemical heterogeneity of [ 99m Tc]Tc-iPSMA while maintaining high RCP. The selected conditions could be translated into an all-in-one single-vial proof-of-concept formulation, although further analytical, pharmaceutical and biological development is required before clinical implementation.
Authors
- Léa Rubira (ORCID: https://orcid.org/0000-0002-6343-7811)
- Cyril Fersing (ORCID: https://orcid.org/0000-0002-4455-4641)
- Jade Torchio (ORCID: https://orcid.org/0009-0000-6400-6143)
- Lina Stamboul
- Jeanne Chillard
Institutions
- École Nationale Supérieure de Chimie de Montpellier (FR)
- Centre National de la Recherche Scientifique (FR)
- Institut des Biomolécules Max Mousseron (FR)
- Institut Regional du Cancer de Montpellier (FR)
Publication Details
- Journal
- Frontiers in Nuclear Medicine
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3389/fnume.2026.1980206
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00